Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
Wang B, Ou Z, Zhong W, Huang L, Liao W, Sheng Y, Guo Z, Chen J, Yang W, Chen K, Huang X, Yang T, Lin T, Huang J.
Wang B, et al. Among authors: huang l, huang x, huang j.
Cancer Immunol Res. 2023 Dec 1;11(12):1656-1670. doi: 10.1158/2326-6066.CIR-23-0117.
Cancer Immunol Res. 2023.
PMID: 37847894